opicinumab

Opicinumab is a fully human monoclonal antibody developed as an experimental therapy for demyelinating diseases such as multiple sclerosis (MS) and acute optic neuritis. Its mechanism of action is antagonism of the LINGO-1 protein, a negative regulator of oligodendrocyte differentiation and axonal regeneration in the central nervous system. By blocking LINGO-1, opicinumab aims to promote the maturation of oligodendrocytes—the cells responsible for producing and maintaining myelin sheaths around nerve fibers—thereby facilitating remyelination and potentially reversing or preventing disability progression in MS. Despite promising preclinical data and early clinical trials, phase II studies did not demonstrate significant efficacy on primary endpoints in relapsing or progressive MS populations. As a result, further development has been discontinued by its developer[2][3][4][5].

Brand names

opicinumab

Other names

anti-LINGO-1anti-LINGO1anti-LINGO 1BIIB033BIIB-033BIIB 033